G

G. of GPR133 (H543R) did not respond to antibody activation, suggesting that the effect is cleavage dependent. Finally, we demonstrate the antibody-mediated activation of WT GPR133, but not the cleavage-deficient H543R mutant, was reproducible in patient-derived GBM cells. These findings provide a paradigm for modulation of GPR133 function with biologics and support the hypothesis that this intramolecular cleavage in the N-terminus modulates receptor activation and signaling. Keywords: adhesion G protein-coupled receptor, antibody, signaling, dissociation Abbreviations: aGPCRs, adhesion G protein-coupled receptors; BSA, bovine serum albumin; CTF, C-terminal fragment; FBS, fetal bovine serum; GAIN, GPCR autoproteolysis-inducing; GBM, glioblastoma; GPS, GPCR proteolysis site; HA, hemagglutinin; HEK293T, Human embryonic kidney 293 T; HTRF, homogeneous time resolved fluorescence; IBMX, 3-isobutyl-1-methylxanthine; NTF, N-terminal fragment; pCTRL, control peptide; PTX, pentraxin domain name Adhesion G proteinCcoupled receptors (aGPCRs) represent the second largest subfamily within the GPCR superfamily (1,?2) and have been implicated in numerous physiological processes and disease mechanisms (3, 4, 5). Adhesion GPCRs are structurally characterized by an intracellular C-terminus, a seven transmembrane segment domain name and a large extracellular N-terminus (2, 6, 7). While unique functional domains within the N-terminus are thought to mediate receptor-specific interactions with adjacent cells or the extracellular matrix (2), almost all aGPCRs share a conserved GPCR autoproteolysis-inducing (GAIN) domain name within the N-terminus. This domain name catalyzes intramolecular autoproteolytic cleavage at the GPCR proteolysis site (GPS) within the N-terminus, resulting in an N-terminal fragment (NTF) and a C-terminal fragment (CTF) (8). A prevalent hypothesis in the field is usually that binding of ligands from adjacent cells or the extracellular matrix to the N-terminus, as well as mechanical stimuli, induce conformational changes or NTF-CTF dissociation (3, 9, 10, 11, 12). These events, in turn, enable the sequence (9, 13, 14, 15, 16, 17, 18, 19), a tethered internal agonist peptide sequence immediately distal to the GPS, to activate signaling (3, 20). However, the exact activation mechanisms likely differ among users of the aGPCR family and are not well characterized. Our group recently demonstrated part of the mechanism that mediates the activation of GPR133 (ADGRD1), a member of group V of aGPCRs (2) implicated in the pathogenesis of glioblastoma (GBM) (21, 22), an aggressive brain malignancy (23). The N-terminus of GPR133, which contains a pentraxin (PTX) domain name, undergoes autoproteolytic cleavage almost immediately after protein synthesis (24). However, NTF and CTF stay noncovalently bound to CGP60474 each other until they are trafficked to the plasma membrane, where their dissociation occurs and correlates with increased signaling mediated by Gs, resulting in activation of adenylate cyclase and elevation in cAMP levels (21, 24, 25, 26, 27). Our finding that dissociation of NTF and CTF correlates with increased signaling is in accordance with the previous observation that this CTF of GPR133, when expressed without the NTF, demonstrates hyperactive signaling relative to its full-length counterpart (9). Collectively, our data suggest that the cleaved but noncovalently associated NTF-CTF holoreceptor is usually signaling qualified, but its dissociation at the plasma membrane enables full activation of receptor signaling. Here, we demonstrate that antibodies targeting epitopes outside of the GAIN domain name of the N-terminus of GPR133 increase receptor-mediated Gs signaling and cAMP levels. Preventing specific antibody binding by deleting the targeted epitope abolishes the effect. The antibody-mediated activation is dependent on receptor cleavage, because antibodies fail to modulate signaling of a cleavage-deficient GPR133 mutant (H543R). These findings suggest that GPR133 function can be modulated by antibodies, Rabbit polyclonal to CD14 and likely other biologics as well, which can be used as molecular tools in the study of receptor activation but also as therapeutic platforms in the CGP60474 context of GBM and possibly other malignancies, where GPR133 plays important roles. Results Activation of GPR133 signaling with antibodies against its N-terminus To test whether GPR133 signaling is usually modulated by antibodies binding to the extracellular N-terminus, we transfected Human embryonic kidney 293T (HEK293T) cells with GPR133 tagged with an N-terminal hemagglutinin (HA) CGP60474 and a C-terminal FLAG epitope (Fig.?1test. test). We CGP60474 then treated the HEK293T cells with either a mouse monoclonal antibody (8E3E8) that we raised against the PTX domain name of GPR133.